OBJECTIVES To assess whether the evolution of two consecutive high-resolution computed tomography (HRCT) scores in patients with cystic fibrosis (CF) has prognostic value. METHODS A longitudinal retrospective study was performed to research adult patients with CF. Two consecutive HRCT studies were scored using Bhalla and Brody II scoring scales by two senior radiologists. Annual scoring changes for each scale were calculated and correlated with annual FEV1% decline, with pulmonary exacerbations and number of antibiotic treatments. RESULTS We selected sixty-four adult patients. The median interval between the two HRCTs was 3.88 ± 1.59 years. The mean spirometric values showed dynamic lung volumes lower than the general population; globally, there was a worsening of respiratory function over time. The change in the annual HRCT scores was positive on both scales, indicating a worse structural situation over time. The Brody II scale annual change showed a significant statistical correlation with a decline in the annual FEV1%, exacerbations and number of oral antibiotic treatments. In contrast, for the Bhalla scale, the relationship was moderately inverse with exacerbations and with the number of oral treatments. No statistically significant relationships were found for the change in the annual FEV1% and exacerbations or number of antibiotic treatments. The interobservational and intraobservational agreements were very strong in both scales. CONCLUSIONS The annual evolution of the Brody II HRCT scoring system demonstrated a predictive value and correlated with FEV1% decline, pulmonary exacerbations and oral antibiotic treatments. KEY POINTS • HRCT evolution has prognostic value in cystic fibrosis. • Temporal evolution for the Brody II score is useful for clinical follow-up. • Brody II score changes correlate with FEV1% decline, pulmonary exacerbations and number of antibiotic treatments.

中文翻译：

---

CT扫描评分系统在囊性纤维化成年患者中的预测价值。

目的评估囊性纤维化（CF）患者连续两次高分辨率CT（HRCT）评分的演变是否具有预后价值。方法进行了一项纵向回顾性研究，以研究成年CF患者。两名资深放射科医生使用Bhalla和Brody II评分量表对两项连续的HRCT研究进行了评分。计算每个量表的年度评分变化，并将其与年度FEV1％下降，肺病恶化和抗生素治疗次数相关。结果我们选择了64名成年患者。两次HRCT之间的中位间隔为3.88±1.59年。平均肺活量测定值显示动态肺活量低于一般人群。在全球范围内，随着时间的推移呼吸功能恶化。在这两个量表上，年度HRCT分数的变化均为正，表明随着时间的推移，结构状况恶化。Brody II量表的年度变化与年FEV1％的下降，恶化和口服抗生素治疗次数的减少显示出显着的统计学相关性。相反，就Bhalla量表而言，这种关系与病情加重和口服治疗的次数呈中等程度的反比。未发现年度FEV1％的变化和加重或抗生素治疗次数的统计显着相关。观察间协议和观察内协议在两个尺度上都非常强。结论Brody II HRCT评分系统的年度发展具有预测价值，并且与FEV1％下降，肺病恶化和口服抗生素治疗相关。要点•HRCT演变对囊性纤维化具有预后价值。•Brody II评分的时间演变可用于临床随访。•Brody II评分变化与FEV1％下降，肺病恶化和抗生素治疗次数相关。